Hepatitis C Vaccine Delivered By Inovio Biomedical’s Electroporation System Shows Increased T-Cell Responses And Reduced Viral Loads, Study
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the evolvement of DNA vaccines using electroporation-based DNA delivery, announced today that its husband, Tripep AB, reported additional interim results from its ongoing phase I/II clinical study of its ChronVac-C® salutary DNA vaccine, which is delivered using Inovio’s electroporation-based DNA distribution method. These preliminary results are from the from the word go two patients in the intermediate dose group to complete treatment against hepatitis C virus infection. Samples taken before, during and after treatment showed that the viral levels in blood decreased up to 87% and 98%, individually, during treatment. Coincident activation of the patients’ T-cell responses to the hepatitis C virus was recorded in conjunction with the viral load reductions. Inovio’s electroporation delivery technology is intended to enhance the potency of DNA vaccines against cancers and transmissible diseases.
ChronVac-C® is a beneficial vaccine given to individuals already infected with the hepatitis C virus with the have designs on of clearing the infection from the liver by boosting the body’s vaccinated reaction against the virus. This clinical look is being conducted at the Transmissible Disease Clinic and Center through despite Gastroenterology at the Karolinska University Hospital in Huddinge and Solna, respectively, in Sweden. The intended enrollment of 12 patients is being divided into three dosage groups with increasing doses of ChronVac-C. Each philosophical receives four vaccinations lone month apart. After the last vaccination, patients are followed for another six months. The study’s main determination is to assess safe keeping. It is also testing whether the treatment boosts the inoculated response (immunogenicity) to HCV and its effect on virus replication in the liver. If the patient is completely virus-democratic six months after completing treatment, he/she will be considered cured.
In the assemblage treated with the sick amount of ChronVac-C, transient activation of T-cell responses was recorded but no reduction of viral load. In the group treated with the intermediate dose, T-cell responses were recorded simultaneously with clear reductions in the serum levels of hepatitis C virus, suggesting that the therapy is dose-dependent. No severe adverse events have been recorded. All three patients in the high dispense group have started therapy and we expect results from this gang during the fall.
Avtar Dhillon, MD, Inovio’s president and CEO, stated: “Recognizing that this is still a deeply limited patient citizens and data series, we are encouraged by the results of this hepatitis C virus phase I/II clinical study. Existing treatments are hard on patients, commonly described as being similar to chemotherapy, and are exclusively effective in roughly half of patients treated. We are pleased that to time this therapy has not produced these chemotherapy-delight in side effects nor serious adverse events and, without yet reaching the highest amount levels, is producing indubitable results. The fact that there may be a portion-dependent correlation between T-cell responses generated and reduction in hepatitis C viral stack may bent ChronVac-C, in which we have partial ownership, to potentially play a job as a first-line therapy or as an adjunct to existing therapies. We look forward to the continuing clinical assessment of this promising DNA vaccine candidate.”
The total sell instead of therapies against hepatitis C infections was estimated by Rodman & Renshaw to be enclosing $3.5 billion in 2005 and to grow to more than $8.0 billion in sales by 2012.
About Inovio Biomedical Corporation
Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based immunotherapies and DNA vaccines. Inovio is a chairlady in developing generous applications of electroporation using abstract, controlled electrical pulses to boost waxing cellular comprehension of a useful biopharmaceutical. Humanitarian figures has shown that Inovio’s electroporation-based DNA distribution technology can significantly increase gene style and unaffected responses from DNA vaccines. Immunotherapy partners register Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, Native Cancer Inaugurate, and International Aids Vaccine Initiative. Inovio’s technology is protected by an vast patent portfolio covering in vivo electroporation. More information is available at http://www.inovio.com.
This request release contains on the cards forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Realized events or results may differ from our expectations as a result of a loads of factors, including the uncertainties native in clinical trials and product situation programs (including, but not reduced to, the fait accompli that clinical results referenced in this delivering may not be indicative of results achievable in other trials or in the course of other indications and that results from one investigation may naturally not be reflected or supported by the results of other almost identical studies), the availability of funding to support continuing research and studies in an elbow-grease to prove safety and efficacy of Inovio’s technology as a delivery mechanism, the availability or unrealized availability of another therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any remedy or treatment that Inovio and its collaborators hope to develop, ranking of capability opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or impinge on or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can resources or aside other significant resources that may be of the essence to prosecute, protect or defend them, the honest of corporate expenditures, assessments of our technology by aptitude corporate or other partners or collaborators, top-hole store conditions, the actual size and solidity of the market(s) developed for our therapies, if any, and other factors set forth in our Annual Explore on Make up 10-K for the year ended December 31, 2007, our 10-Q owing the three months ended Pace 31, 2008 and other regulatory filings from things to time. There can be no assurance that any product in our product in work will be successfully developed or manufactured, that unalterable results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein resolve be proved accurate.
Inovio Biomedical Corporation